The FASTEST study was a phase 3, multicenter, double-blind, randomized, placebo-controlled trial. It investigated recombinant factor VIIa versus placebo in patients with spontaneous intracerebral hemorrhage (ICH) administered within 2 hours of symptom onset. Recombinant factor VIIa slowed the growth of hematomas. However, it did not improve the patients' functional outcomes. The treatment showed a slightly increased risk of life-threatening thromboembolic complications. Further testing of recombinant factor VIIa in patients at greatest risk of continued bleeding is ongoing.